Herbalife Nutrition Ltd. HLF

Key data

The business

Herbalife makes powders, shakes, teas and supplements and sells almost none of it in stores. It moves product through millions of independent distributors across 90-plus countries who buy at a discount and resell, mostly face to face, often out of neighborhood nutrition clubs where a shake is mixed and served on the spot. The distributor, not the person who drinks the shake, is the real customer: Herbalife records a sale when the distributor buys, not when the end user does. That is the whole engine and its whole weakness. When recruiting slows, the base of buyers shrinks, and the company leans on price increases and its most loyal sellers to hold the line.

The moat is a 45-year-old distribution network and the loyalty of sellers who have built small businesses on it, held together by the cost of walking away from a book of customers. It is not a product moat, a protein shake is a protein shake. It is a people moat, and people moats erode quietly.

The numbers

Revenue peaked at $5.8B in 2021, fell three straight years, and has since ticked back up. The quarters show the same steadying, then a June loss that is entirely a financing event, not an operating one.

The June quarter's loss came from a $94.6M charge to refinance debt; operating income was still $128.3M and adjusted EBITDA $166.6M. Strip the charge and the quarter earned $0.51, a record top line up 5.4% against last year. First-half revenue of $2.64B is up 6.6% year on year, but the margin bridge is the tell: the gain is price, roughly 64 basis points of pricing benefit, not more product moving. That is the consumer-lens warning, ticket rising while the count of buyers is the thing to watch.

The debt is the story the multiple hangs on, and it is moving the right way.

At 5x forward earnings against roughly $450M of yearly free cash flow aimed at debt, this is a deleveraging equity, not a compounder. Every dollar of net debt retired moves value from lenders to shareholders. What the market prices is terminal volume decline, a melting business worth its cash flows and no more. The variant is narrow and testable: whether the club format and pricing hold the buyer base flat long enough for debt paydown to re-rate the equity. The one print that settles it is regional volume points in the coming 10-Qs.

Management

The capital-allocation record is the scar. Herbalife spent about $1.0B buying back stock in 2021 at prices three to four times today's, plus $146.7M in 2022, much of it funded with the debt now weighing on the balance sheet, and book equity is negative as a result. Buybacks have since stopped, $8.2M in 2025, and every spare dollar now goes to debt, the right move made late. Insiders were net sellers over the past year, $2.55M sold, led by Lamberti's $1.82M in May 2026 and Hicks's $496K, against $182K bought; plan status is not disclosed on any of them, so read the sales as soft, not damning. One officer, Cloud, bought $152K in November 2025.

How it fails or surprises you

The seller base erodes faster than price can cover. Growth is price-led and the filing text pulled this run does not break out volume points. If active distributor counts and volume fall while pricing tops out, revenue rolls over and the paydown math breaks. Two down volume quarters in the regional tables invert the thesis.

The leverage leaves no room for a bad year. Net debt is about $1.65B against roughly $528M of TTM adjusted EBITDA, near 3.1x, with interest coverage around 2.4x. The June refinancing charge shows the maturity risk is live; a weak year into a maturity wall forces a bad deal. Watch interest coverage falling below 2x.

The equity re-rates on deleveraging alone (right tail). Retire $1B of debt over two to three years and that value lands straight on the equity. If volume merely stabilizes and the multiple drifts back to even 8x, the low end of its own twelve-year range, the stock roughly doubles with no growth at all. The market pays nothing for this today; two straight quarters of flat-to-up volume is the trigger.

Closing thoughts

The volume trend in the next two quarters tells you whether the business is stabilizing or melting, but paying down $1.65B of net debt takes two to three years of clean cash flow with no miss. Given the price paid, the fatter tail is arguably the upside, but the left tail is real and permanent: negative equity and 3.1x leverage mean a genuine volume collapse takes the whole equity, while stabilization is worth a double from debt paydown alone. My judgment, not a number: the odds favor stabilization over collapse, but the balance sheet gives no margin for being wrong.

The bet is still that the seller base keeps buying shakes and supplements to resell while the company raises prices and pays down debt. It breaks the day volume points and active distributor counts fall together for two straight quarters while price increases stall; that pair, disclosed in the regional tables of the coming filings, tells you first whether you own a deleveraging turnaround or a melting ice cube.